Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Dosage Regimen: Individualization

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-Term Neuroradiological and Clinical Evaluation of NBIA Patients Treated with a Deferiprone Based Iron-Chelation Therapy.

Journal of clinical medicine·2022

Same author

Consensus on the treatment of dysphagia in Parkinson's disease.

Journal of the neurological sciences·2021

Same author

A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value.

Journal of neurology·2021

Same author

Dual task gait deteriorates gait performance in cervical dystonia patients: a pilot study.

Journal of neural transmission (Vienna, Austria : 1996)·2021

Same author

A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial.

Journal of Parkinson's disease·2021

Same author

The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.

Drug design, development and therapy·2021

Same journal

Primary Sjogren syndrome with suspected central nervous system inflammatory involvement.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026

Same journal

Efficacy of repetitive transcranial magnetic stimulation for post-stroke spasticity: a meta-analysis of randomized controlled trials.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026

Same journal

Diverging trends in motor neuron disease burden in China: an ageing-driven increase despite declining age-standardised rates - a GBD 2021 analysis.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026

Same journal

Efficacy and safety of extended-interval dosing of natalizumab in multiple sclerosis: a systematic review and meta-analysis with subgroup evaluation.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026

Same journal

Ultrashort echo time magnetic resonance angiography for embolized intracranial aneurysm with coil protrusion into the small parent vessel in the posterior circulation.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026

Same journal

Mixing apples and antibodies: when the Cochrane average obscures the evidence in Alzheimer's disease.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Optimising levodopa therapy.

Giovanni Abbruzzese¹

¹Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Via De Toni 5, Genoa, Italy. giabbr@csita.unige.it

Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

|April 22, 2009

Summary

This summary is machine-generated.

Levodopa is the primary Parkinson's disease treatment, but its effectiveness wanes over time, leading to motor fluctuations. Optimizing levodopa use remains crucial for managing Parkinson's disease symptoms.

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Related Experiment Videos

Last Updated: Jun 23, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Area of Science:

Neuroscience
Pharmacology
Neurology

Background:

Levodopa is the established gold standard for symptomatic Parkinson's disease treatment.
Long-term levodopa use (4-5 years) often results in diminished clinical efficacy.
This decline is associated with the 'long-term levodopa syndrome' and altered drug response.

Purpose of the Study:

To explore strategies for extending the clinical benefits of levodopa.
To investigate methods for delaying the onset of motor complications in Parkinson's disease.
To address the suboptimal use of levodopa regarding administration and dosage.

Main Methods:

This study is a review of current scientific literature and debates.
Analysis of pharmacodynamic changes related to long-term levodopa administration.
Examination of therapeutic strategies for Parkinson's disease management.

Main Results:

Long duration response (LDR) transitions to short duration response (SDR), causing clinical fluctuations.
Current strategies aim to maximize levodopa benefits and postpone motor complications.
Optimal administration and individualized dosing remain significant challenges.

Conclusions:

The long-term efficacy of levodopa in Parkinson's disease is limited by the development of motor fluctuations.
Further research is needed to optimize levodopa administration and dosing strategies.
Achieving optimal levodopa use across all disease stages requires continued scientific focus.